52. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
53. Wallentin L, Lagerqvist B, Husted S, Kontny F. Stable E, Swahn E. Outcome at 1 year after an invasive compared with a non –invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomisedtrial. Lancet. 2000;356:9-16.
54. Tajer C, Mauro V, Charask A. Tratamiento de la angina inestable. En: Doval H, Tajer C: Evidencias en Cardiología III. Ediciones GEDIC. 2003;12:2-7-
55. Alexander R W, Pratt CM, Ryan TJ, Roberts R. Diagnóstico y Tratamiento de los pacientes con Infarto agudo de Miocardio En: O´Rourke RA, Fuster V, Alexander RW, Roberts R, King SB, Wellens HJ (eds): El Corazón. Hurst, 10ma ed. New York: McGraw-Hill;2001:321-377.
56. Boersma E, Maas AC, Deckers JW, Simmons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771-5.
57. Every. NR, Weawer WD.: Prehospital Treatment of Myocardial Infarction. Current Problems in Cardiology 2005;29:3-50.
58. Herlitz J, Hartford M, Aune S. Delay tirne between onset of myocardial infarction and start of thrombolysis in relation to prognosis. Cardiology 2004;2:347-35.
59. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation. 2004;110:e82-292
60. López Grillo L, Núñez N, Octavio JA, Pérez González J. Asistencia cardiovascular en el tercer nivel de atención médica: tendencia en Venezuela año 1958 a 1994 y 1999. Av Cardiol. 2001;21(2):58-67.
61. Sizot Meza J. Mortalidad por infarto agudo del miocardio en Chile 1090-2001. Rev Med Chile. 2004;132:1227-1233.
62. Marrugat J, Elosúa R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol. 2005;55:337-46.
63. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med. 2002;5:27-37.
64. Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features: BNJ. 1994;308:883-6.
65. Morise AP, Haddad WJ, Beckner D. Development and validation of clinical score to stimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. Am J Med. 1997;102:350-6.
66. Pryor DB, Shaw L, McCants CB. Value of the history and physical in identifying patients at increase risk for artery disease. Ann Intern Med. 1993;118:81-90.
67. Ho KT, Miller TD, Hodge DO, Bailey Kr, Gibsons RJ. Use of a simple clinical score to predict prognosis of patients with normal or mildly abnormal resting electrocardiography finding undergoing evaluation for coronary artery disease. Mayo Clin Proc. 2002;77:515-21.
68. Wenger NK. You ¨ve come a long way, baby: cardiovascular and disease in women: problems and prospects. Circulation. 2004;109:558-60.
69. Harney P. Coronary artery disease in young women: the menstrual cycle and other risk factors. Ann Intern Med. 2001;135:1002-4.
70. Zamora A, Marrugat J. Pronóstico de la cardiopatía isquémica en la diabetes. Rev Esp Cardiol 2002;55:751-62.
71. O´Donnell CJ, Elousa R. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study. Rev Esp Cardiol. 2008;61(3):299-310.
72. Westerhout C., Fu Y., Lauer M., y col. Short- and long-term risk stratification in acute coronary syndromes. The added value of quantitative ST-segment depression an d multiple biomarkers. J Am Coll Cardiol 2006;48:939-47.
73. Sacks FM. Pfeffer MA, Moye LA. The efffect of pravastatina on coronary events after myocardial infarction in patients with average cholesterollevels. Cholesteroland Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
74. Hasdai D, Porter A, Rosengren A, Behar S, Boyko V. Battler A. Effect of gender on outcomes of acute coronary syndromes. Am J Cardiol. 2003;91:1466-9.
75. Ferreiros E, Di Toro D, Blanco P, Cragnolino R, Fuselli JJ, Boissonnet C, et al. Impacto del tabaquismo en la evolución de los pacientes internados por síndromes isquémicos agudos. Rev Arg Cardiol. 2004;72(1):14-20.
76. Paniagua-Contreras G, Monroy-Pérez E, Vaca-Pacheco S, Valle-Patiño A et al Factores de riesgo coronario en pacientes ambulatorios del Estado de México Rev Med Hosp Gen Mex 2002;65 (2): 68-71.
77. GRACE Investigators Rationale and desing of the GRACE (Global Registry of Acute Coronary Events) project a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001;141:190-9.
78. Birkhead JS, Walker L, Pearson M, Weston C. Cunningham AD, Rickards AF. Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial infarction Project (MINAP). Heart. 2004;90:1004-9.
79. Haidi D, Behar S, Boyko V, Danchin N, Bassand JP, Battler A. Cardiac biomarkers and acute coronary syndromes – The Euro Heart Survey of Acute Coronary Syndromes Experience. Eur Heart J. 2003;24:1189-94.
80. Prado E. Síndrome Coronario Agudo en el Centro Diagnóstico Fabricio Ojeda año 2005-2006. Trabajo de Maestría. Estado Anzoátegui. Venezuela. 2008.
81. Hochmanm JS, McCabe CH, Stone PH. For the TIMI investigators: Outcome and profile of women and men presenting with acute coronary syndromes: A report from TIMI IIIB. J Am Coll Cardiol. 1997;30:141.
82. Scirica BM, Moliterno DJ, Every NR. The GUARANTEE Investigators: Differences between men and women in the management of unstable angina pectoris (the GUARANTEE Registry). Am J Cardiol. 1999;84:1145.
83. Hochmanm JS, Tamis JE, Thompson TD. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronaries Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999;341:226.
84. Stone PH, Raabe DS, Jaffe AS, Gustafson N, Muller JE, Turi ZG, et al. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol. 1988;11:453-463.
85. Behar S, Rabinowitz B, Zion M, Reicher – Reiss H,Kaplinsky E, Abinader E. Inmediate and long-term prognostic significance of a first anterior versus first inferior wall Q-wave acute myocardial infarction. Am J Cardiol. 1993;72:1366-1370.
86. García Díaz, F, Sánchez JJ, Frías Ochoa YJ, López-Cuervo JF. El electrocardiograma en la estimación inicial del pronóstico de pacientes con infarto agudo de miocardio. Med Intensiva. 2000;24:220-229.
87. Bosch X, Sambola A, Arós F, López-Bescós L, Mancisidor X, Claramonte R. Utilización de trombolisis en los pacientes con infarto agudo de miocardio en España: Observaciones del estudio PRIAMHO. Rev Esp Cardiol. 2000;53:490-501.
88. Katritsis D, Karvouni E, Webb-Peploe MM. Repefusion in acute myocardial infraction. Current concepts. Prog cardiovas Dis. 2003;45:481-96.
89. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
90. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-60.
91. Rawlws J. GREAT: 10 year survival of patients with suspected acute myocardial infarction in a randomised comparison of prehospital and hospital thrombolysis. Heart. 2003;89(5):563-4.
92. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al.; for the Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators*Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty. Data From the CAPTIM Randomized Clinical Trial Circulation. 2003;108:2851-2856.
93. Eagle KA, Goodman SG, Avezun A. Practice variation and missed opportunities for reperfution in ST-segment-elevation myocardial infarction: Findings form the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002; 359:373-392.
94. Bosh X, Bórquez E, Verbal F, Sanchís J. Tratamiento de la insuficiencia cardiaca en la fase aguda del infarto de miocardio. Rev Esp Cardiol (supl). 2006;6:15B-30B.
95. Bueno H, Bardají A, Fernández-Ortiz A, Martí H y Heras M. (en nombre de los investigadores del Estudio DESCARTES: Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal Español) Rev Esp Cardiol. 2005;58:244–252.
96. Killip T, Kimball J. Treatment myocardial infarction in a coronary care unit. A two years experience with 250 patients. Am J Cardiol. 1967;20:457-64.
97. Pfeffer M, McMurray J, Velázquez E, Rouleau J, Kober L, Maggioni. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
98. Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends (1994–1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction. Am Heart. 2001;141:65–72.
99. Worner F. Viles D, Diez-Aja S. Epidemilogía y pronóstico de la insuficiencia cardiaca postinfarto. Rev Esp Cardiol. 2006;6:3B-14B.
100. Fincke, R, Hochman, JS, Lowe, AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality incardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340.
101. Picard, MH, Davidoff, R, Sleeper, LA, et al. Echocardiographic predictors of survival and response to early revascularization cardiogenic shock. Circulation. 2003;107:279.
102. Arós F, Cuñat J, Loma-Osorio A, Torrado E, Bosch X, Rodríguez JJ, et al. PRIAMHO II Study. Tratamiento del infarto agudo de miocardio en España en el año 2000. El estudio PRIAMHO II. Rev Esp Cardiol. 2003;56:1165-73.
103. Bodí V, Sanchis J, Llácer A, Fácila L, Núñez L, Pellicer M, et al. Indicadores pronósticos del síndrome coronario agudo sin elevación del segmento ST Rev Esp Cardiol. 2003;56:857– 864.
104. Cequier A, Bueno H, Augé JM, Bardají A, Fernández-Ortiz A, Heras M. Características y mortalidad del infarto agudo de miocardio tratado con intervencionismo coronario percutáneo primario en España. Resultados del Registro TRIANA 1. Rev Esp Cardiol. 2005;58:341-50.
105. Sanborn, TA, Sleeper, LA, Webb, JG, et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 2003;42:1373.


Bibliografía Consultada

1. Braunwald E, Libby P, Bonow R, Mann DL, Zipes DP. BRAUNWALD´S HEART DISEASE: a textbook of Cardiovascular Medicine. 8th ed. Philadelphia (USA): Saunders Elsevier; 2007.
2. Canon CP, Braunwald E. Management of Acute Coronary Syndromes. 2a ed. Totowa (NJ): Humana Press; 2003.
3. Fuster V, Walsh RA, O´Rourke RA, Poole-Wilson P. HURST´S The HEART. 12th ed. Deepak Bhatt (NY); 2007.
4. Kaplan NM, Flynn JT. Kaplan´s Clinical Hypertension. 9 th ed. Dallas (USA): Lippincott Williams and Wilkins; 2007.
5. Topol EJ. Acute Coronary Syndromes. 3a ed. NY (USA): Merced Dekker; 2005.
6. Topol EJ, Califf R, Prystowsky E, Thomas J, Tompson P. Textbook of Cardiovascular Medicine. 3a ed. Ohio (NY): Lippincott Williams and Wilkins; 2007.
7. Zipes DP, Libby P, Bonow R, Braunwald E. Brauunwald Tratado de Cardiología. Texto de Medicina Cardiovascular. 7ª ed. Madrid (Esp): Elsevier; 2006.